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The purpose of this thesis is to provide an alternating harvest method for enhancing 
Factor VIII (FVIII) yield in alternating tangential flow (ATF) perfusion culture. This goal 
was accomplished by developing a modified harvest system composed of a check valve, a 
pinch valve, and a timer.  
This thesis was composed of three studies. In the first study, three cell retention devices, 
an ATF system, a spin-filter, and a Centritech Lab III centrifuge was evaluated for the 
production of recombinant human Factor VIII (rhFVIII) co-expressed with von Willebrand 
factor (vWF). From the results, it was found that the FVIII activity (FVIII:C) in bioreactor 
was significantly higher in the ATF perfusion culture than two other perfusion cultures. 
Moreover, the FVIII:C recovery yield was unexpectedly low in the ATF perfusion culture. 
Therefore, the reasons for this low FVIII:C recovery yield were studied. It was revealed 
that the inactivation and the surface adsorption of FVIII onto the harvest bag were not the 
main reasons for the low yield in the ATF perfusion culture. The FVIII:C recovery yield 
was not increased by the use of a hollow fiber filter with 0.5 mm pore size instead of 0.2 
mm pore size. Additionally, the retention of FVIII molecules by the hollow fiber filter was a 
dominant factor in the low FVIII:C recovery yield in the ATF perfusion culture. It was 
demonstrated that FVIII yield was significantly improved by controlling transmembrane 
pressure (TMP) across the hollow fiber filter membrane. Taken together, these results 
suggest that TMP control could be an efficient method for the enhancement of FVIII yield 
in an ATF perfusion culture.  
In the second study, it was described the development of a modified harvest system to 
enhance FVIII yield in ATF perfusion culture. The main innovation of the modified harvest 




In the third study, the modified harvest system was applied to perfusion cultures of 
Chinese hamster ovary (CHO) cells, which co-express both rhFVIII and vWF. The 
modified harvest system showed comparable cell growth with the conventional harvest 
system using a peristaltic pump. The perfusion rate was successfully controlled using the 
system. In addition, the modified harvest system achieved an approximately 13.6-fold 
increase in the final recovery yield of FVIII:C and a 1.47-fold increase in the product yield 
of FVIII:C compared with a peristaltic pump. Enhancement of the yield of FVIII:C 
resulted from the reduction of FVIII antigen (FVIII:Ag) retention. As a result of TMP 
measurement, the reduction of the retained FVIII:Ag was due to the increased TMP, which 
was caused by the characteristic function of a check valve, compared with a peristaltic 
harvest system.  
In conclusion, the modified harvest system developed in this thesis could be useful to 
enhance the product yield of other recombinant proteins in ATF perfusion culture. Another 
important point is that the system provides a promising tool to solve the fouling problem in 
the filtration-based perfusion system, especially in ATF perfusion culture. 
 
Key words: Factor VIII, ATF perfusion, Modified harvest system, Transmembrane 
pressure, Pinch valve, Check valve 
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1.1 Factor VIII 
Factor VIII (FVIII) is an X-linked gene product that accelerates the activation of 
Factor X by Factor IX in the coagulation process. Human FVIII is an essential cofactor in 
the blood coagulation cascade. A deficiency in the amount of FVIII in the blood results in 
hemophilia A which is an inherited bleeding disorder that prevents the blood from clotting 
properly. Hemophilia A is inherited as a chromosome X-linked recessive disorder 
(Mannucci and Tuddenham, 2001) (Fig. 1.1).  
There is currently no curative treatment for hemophilia A patients. The main 
treatment for hemophilia is called replacement therapy. Concentrates of plasma-derived or 
recombinant human FVIII is slowly injected into a vein. These infusions help replace the 
deficient or not enough FVIII. Plasma-derived FVIII is made from human plasma. Plasma 
donations are pooled together. Then, the plasma is fractionated into different products. One 
of the main products is the plasma-derived FVIII. Although the safety of plasma-derived 
products from the blood-borne transmission of viruses such as hepatitis virus or human 
immunodeficiency virus is greatly improved, there are still the uncertainty of the potential 
risk of viral transmission. Also, there are some limitations to produce the plasma-derived 
FVIII due to the limited supply of the human plasma. For this reason, the used amount of 
recombinant FVIII tends to increase recently. 
The full length FVIII is an extremely large heterodimeric glycoprotein with a 
molecular weight of 330kDa (Fig. 1.2). The unprocessed FVIII contains 2332 amino acids, 
which are arranged in 6 domains (heavy chain, A1-A2-B and light chain, A3-C1-C2) 
(Bihoreau et al., 1991).  
FVIII undergoes processing prior to secretion into blood. It is released into the 
circulation as a set of heterodimeric proteins (Lenting et al., 1998). The plasma purified 




Fig. 1.1 Hemophilia transmission by a carrier mother and hemophilic father There 
are two ways the hemophilia gene can be transmitted. If the mother is a carrier, then 50% 
of her sons will have hemophilia and 50% of her daughters will also be carriers. If the 
father has hemophilia, his sons will be unaffected, as it is an X-linked disorder. All of his 
daughters will be carriers for the disorder. X: X chromosome, Y: Y chromosome, Red X: 







Fig. 1.2 Schematic model showing the domain structure of Factor VIII (Lenting et al., 
1998) Mature factor VIII consists of 2332 amino acids, which are arranged in a discrete 
domain structure: A1 (residues 1-336), A2 (373-710), B (741-1648), A3 (1690-2019), C1 
(2020-2172), and C2 (2173-2332). The A domains are bordered by acidic regions a1 (337-

















composed of domains A3-C1-C2 with a molecular weight of 80kDa. The heavy chain has 
a molecular weight of 90-200kDa and is made up of domains A1-A2-B (Kaufman et al., 
1988).  
FVIII exists FVIII/von Willebrand factor (vWF) complex in plasma before 
thrombin activation (Lenting et al., 1998). The whole life span of FVIII is shown in Fig. 
1.3. Upon activation by thrombin, FVIII is released from vWF and a series of specific 
proteolytic degradations occurs (Fig. 1.4). The active FVIII can participate in the intrinsic 
pathway for blood clotting (Fig. 1.5). 
 
1.2 The instability of Factor VIII 
Free FVIII is well known as a unstable protein in plasma as well as in a CHO cell 
culture supernatant (Bangham et al., 1971; Kaufman et al., 1988). In plasma, FVIII is 
usually complexed with vWF which is present in plasma in a large molar excess to FVIII. 
vWF binds to FVIII noncovalently at a constant ratio from 1:1 to 1:70 (Kaufman and Pipe, 
1999; Vlot et al., 1995). the vWF binding protects FVIII from inactivation by activated 
protein C and other proteases (Koppelman et al., 1996).  
Another plasma circulating protein, albumin, may also play a role in stabilizing 
FVIII in vivo. Currently marketed plasma-derived FVIII products and the first generation 
recombinant FVIII (rFVIII) therefore were stabilized by the addition of human albumin as 
a stabilizer during the manufacturing process and during storage (Boedeker, 2001; 
Gomperts et al., 1992; Wang et al., 2003). 
However, because of the potential risk of pathogen contamination of plasma 
products such as human serum albumin, other excipients tend to be used as stabilizers such 
as sucrose or trehalose (Grillberger et al., 2009). The second and third generation rFVIII 
products have albumin-free formulation for safety issues (Boedeker, 2001)(Table 1.1). 
6 
 
Fig. 1.3 The life span of Factor VIII (Lenting et al., 1998) Factor VIII is synthesized by 
various tissues, including liver, kidney, and spleen, as an inactive single-chain protein. After 
extensive posttranslational processing, factor VIII is released into the circulation as a set of 
heterodimeric proteins. This heterogeneous population of factor VIII molecules readily 
interacts with vWF, which is produced and secreted by vascular endothelial cells. Upon 
triggering of the coagulation cascade and subsequent generation of serine proteases, factor 
VIII is subject to multiple proteolytic cleavages. These cleavages are associated with 
dramatic changes of the molecular properties of factor VIII, including dissociation of vWF 
and development of biological activity. After conversion into its active conformation, and 
participation in the factor X activating complex, activated factor VIII rapidly loses its 
activity. This process is governed by both enzymatic degradation and subunit dissociation. 
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Fig. 1.4 Domain structure and processing of FVIII (Pipe, 2009) 








Fig. 1.5 Schematic representation of the blood clotting cascade XII: factor XII 
(Hageman factor), XIIa: activated XII, FXI: factor XI (deficient in hemophilia C), Xia: 
activated FXI, IX: factor IX (Christmas factor; deficient in hemophilia B), IXa: activated 
FIX, VIII: factor VIII (Brinkhous factor, deficient in hemophilia A), VIIIa: activated FVIII, 











Table. 1.1 Characteristics of commercially available FVIII products 
 Brand name Manufacturer Stabilizer 
Plasma-derived 
FVIII 
Hemofil M Baxter Albumin 
Koate-DVI Kedrion Biopharma Albumin 





Albumin (BSA used 
in culture medium) 
Second generation 
Helixate FS CSL Behring Sucrose (human 
plasma protein 
solution used in 
culture medium) 
Kogenate FS Bayer 
Thrid generation 
Advate Baxter Trehalose 
Recombinant FVIII 
(B-domain deleted) 









1.3 The B-domain of Factor VIII 
The B-domain of FVIII is normally processed intracellularly at various positions 
to generate a heavy chain (A1–A2–B) varying from 90 to 200 kDa in size. Two of the 
domains, A and C, have been shown to share amino acid sequences similar to another 
factor protein (Factor V) and are thought to be essential to the coagulant activity of FVIII 
(Pipe, 2009).  
However, the amino acid sequence of domain B is dissimilar to other factor 
protein. Although the role of domain B is not fully understood, it is not thought to be 
directly involved with coagulation and likely associated with intracellular processing of the 
protein (Pipe, 2009; Toole et al., 1986).  
Table 1.2 summarizes the reported function of the B domain. It was reported that 
deletion of this domain results in a smaller protein with no loss of coagulation activity and 
may be efficacious in treatment of hemophilia A in humans (Lind et al., 1995; Pittman et 
al., 1993; Sandberg et al., 2001).  
The smallest FVIII found in plasma is devoid of the heavily glycosylated B-
domain. It is composed of a 90kDa heavy chain and an 80kDa light chain (Fig. 1.4). 
Recently developed recombinant FVIII, Refacto, is a FVIII preparations similar to the 
smallest FVIII protein found in plasma-derived FVIII concentrates. In case of Refacto, the 
B-domain is deleted and replaced with the SQ link of 14 amino acids 
(SFSQNPPVLKRHQR) between the A2 and A3 domains (Sandberg et al., 2001) (Fig. 
1.6). One of the benefits of the deletion of the B-domain is the higher expression level of 
recombinant FVIII in comparison to full-length FVIII (Toole et al., 1986).  
In this thesis, the B-domain deleted FVIII for the production of recombinant 
FVIII was used in order to increase the expression level of FVIII. The B-domain deleted 
FVIII of this thesis contains the SQ link of Refacto between the A2 and A3 domains. 
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Table 1.2 Functions of the B domain in the life cycle of FVIII (Pipe, 2009) 





Enables interaction of factor VIII with chaperone 
proteins that distinguish properly folded tertiary 
structure of proteins; stabilizes folded domains, 
prevents aggregation 
Pipe et al. (1998) 
Secretion 
Interacts with cargo-specific sorting receptor 
complex that enables endoplasmic reticulum to Golgi 
transport; increases secretion efficiency 
Cunningham et al. (2003) 
Moussalli et al. (1999) 
Miao et al. (2004) 
Pipe et al. (2005) 
Zhang et al. (2005) 
Plasma 
Activation 
Possibly shields thrombin activation site from 
premature proteolysis 
Eaton et al. (1986) 
Meulien et al. (1988) 
Pittman et al. (1993) 
Pittman et al. (1994) 
Platelet 
binding 
Decreases the affinity of unactivated factor VIII for 
activated platelets, thus preserving circulating factor 
VIII 
Li and Gabriel (1997) 
Inactivation 
Reduces proteolysis by activated protein C and factor 
Xa 
Khrenov et al. (2006) 
Clearance 
May play a further role in factor VIII quality control 
through interaction with asialoglyprotein receptor 









Fig. 1.6 The B-domain deleted FVIII molecule and the SQ link Full-length FVIII is a 














1.4 von Willebrand factor 
von Willebrand Factor (vWF) is a blood glycoprotein with a molecular weight of 
260 kDa as a monomer (Terraube et al., 2010) (Fig. 1.7). vWF forms large multimers, 
sizing up to 20,000 kDa via N-terminal disulfide bridges (Choi et al., 2007; Furlan, 1996) 
(Fig. 1.8).  
vWF plays a central role in hemostasis. vWF performs its hemostatic function 
through binding to FVIII, to platelet surface glycoproteins, and to constituents of 
connective tissue. In primary hemostasis, vWF initiates platelet aggregation via binding to 
exposed structures of injured vessel walls at physiological high arterial shear rates (Sadler, 
1998).  
In secondary hemostasis, vWF supports platelet aggregation because of its 
binding to FVIII (Fang et al., 2007), therefore protecting the coagulation factor from rapid 
proteolytic inactivation. Furthermore, vWF is thought to assist during platelet aggregation 
by bridging adjacent platelets at high shear rates.  
The function of VWF is strongly shear rate dependent, whereas fluid dynamic 
conditions as well as mechanical forces are crucial for the conformational transition of 
vWF to develop its interaction with endothelial matrix proteins as well as platelets in case 
of vessel injury (Fig. 1.8).  
A deficiency or abnormality of vWF results in the autosomally linked bleeding 
disorder known as von Willebrand disease (vWD) (Ruggeri and Zimmerman, 1987). vWF 
plays a crucial role in regulating FVIII concentration as well as FVIII:C in plasma (Wise et 
al., 1991). vWF also functions as a carrier protein and stabilizer for FVIII protecting it from 







Fig. 1.7 Schematic representation of the pro-polypeptide and multimeric vWF. (a) the 
vWF molecule consists of 4 repeated domains A, B, C and D, the D1-D2 domains 
encompassing the propeptide. Ligand interaction sites are labelled. (b) vWF multimers are 
formed by C-terminal dimerization, followed by N-terminal multimerization, resulting in a 
head-to-head and tail-to-tail arrangement of monomers and juxtaposition of the FVIII 














Fig. 1.8 Schematic illustration of vWF multimers. Upon exposure to high shear stress, 
globular vWF multimers are stretched to covalently associate with each other by forming 













1.5 Production of Factor VIII 
Commercially available rhFVIII products have been produced including full-
length rhFVIII (FL-rhFVIII) and B-domain deleted rhFVIII (BDD-rhFVIII) in either 
Chinese hamster ovary (CHO) cells or baby hamster kidney (BHK) cells (Boedeker, 2001). 
Recently Octapharma AG announced the availability of rhFVIII produced in human 
embryonic kidney cell line, HEK293 (Casademunt et al., 2012). 
The major drawback of rhFVIII production techniques is the low expression 
level due to the large molecular size and structural complexity of FVIII. There are several 
methods to overcome a low expression level, such as deletion of B-domain of FVIII, co-
expression of the von Willebrand factor (vWF)(Berntorp, 1997; Boedeker, 2001; Jiang et 
al., 2002; Kaufman et al., 1988; Kaufman and Pipe, 1999; Weiss et al., 1977), use of 
HKB11 cell as a host cell (Mei et al., 2006), codon optimization of human FVIII cDNAs 
(Ward et al., 2011), bioengineering of FVIII through elimination of a dispensable disulfide 
loop (Selvaraj et al., 2012), development of lentiviral vectors (Mufarrege et al., 2014) and 
over-expression of HSP70 (Ishaque et al., 2007).  
In this thesis, CHO cells co-expressing BDD-rhFVIII and vWF as a stabilizer to 
overcome the low expression level was used. In terms of culture mode, perfusion culture is 
more preferable over batch or fed-batch culture because of a higher instability of FVIII in 
the cell culture supernatant (Boedeker, 2001; Kelley et al., 2010; Weiss et al., 1977). 
Among the various cell retention devices, perfusion cultures with an external cell retention 
device are mainly used in the industrial production of the licensed rhFVIII preparations 
(Boedeker, 2001).  
 
1.6 Perfusion culture 
 Batch, fed-batch and perfusion culture processes are commonly used in the 
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industrial-scale production of recombinant proteins and antibodies (Castilho and Medronho, 
2002). Perfusion culture is not a up-to-date technique, because it has been already used in 
1912 (Burrows, 1912) to keep small pieces of tissue viable for extended microscopic 
observations. The perfusion mammalian cell culture process has been typically used as a 
manufacturing process of unstable recombinant proteins, such as recombinant clotting 
factors, enzymes used in enzyme replacement therapy and other proteins (Chu and 
Robinson, 2001; Pollock et al., 2013). The purpose of perfusion cell culture is the 
enhancement of volumetric productivity by achieving high cell density as compared with 
batch and fed-batch culture methods (Ryll et al., 2000).  
The principle of perfusion culture is a cell culture technique characterized by 
continuous flow of culture medium through the bioreactor with the retention of cells in the 
bioreactor (Fig. 1.9). Fresh medium is continuously added to supply various nutrients for 
cell growth and target protein production. Same amount of cell-free supernatant is 
withdrawn to remove harmful byproducts such as lactate, ammonia and to harvest target 
proteins. The key to successful perfusion culture is the retention of cells in the bioreactor by 
various cell retention devices. A number of cell retention devices are used to separate cells 
from the culture supernatants in perfusion culture (Fig. 1.10). Most cell retention devices 
are based on filtration, gravitational sedimentation, centrifugation (centrifuges, 
hydrocyclones) and ultrasonic separation.  
There are many cell retention devices based on filtration process, such as cross-
flow filter, vortex-flow filter, spin-filter and hollow fiber filter (Voisard et al., 2003). A spin-
filter and a Centritech Lab III system are traditional perfusion devices that have been 
widely used for several decades. ATF system is newly developed device for cell retention 
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 The most common perfusion systems used in commercial processes are spin-
filters (Yabannavar et al., 1992). Spin-filters are commercially available either as internal or 
external devices. Spin-filters was introduced as a cell retention devices for high density cell 
culture of murine leukemia cells in perfusion culture mode in the late 1970s by 
Himmelfarb et al. (1969). Spin-filter is a cylindrical membrane or stainless steel mesh of 
defined pore size. It is mounted on the impeller shaft and placed inside stirred tank 
bioreactor (Fig. 1.11). Fresh medium is pumped into the bioreactor, i.e. outside the spin-
filter and cell-free supernatant is pumped out from inside the spin-filter at the same rate. In 
a spin-filter, cells are separated according to the mesh size of the spin-filter (Himmelfarb et 
al., 1969; Yabannavar et al., 1992). 
 
1.6.2 Centritech Lab III centrifuge 
 Another commercially available and widely used cell retention device is a 
Centritech Lab III centrifuge manufactured by the PneumaticScaleAngelus (Fig. 1.12). The 
cell separation by a Centritech Lab III system is based on sedimentation caused by 
centrifugal force (Johnson et al., 1996; Kim et al., 2008; Tokashiki et al., 1990). Centritech 
Lab III system consists of three parts, centrifuge unit, controller unit and pump unit. In 
Centritech Lab III system, cell-containing supernatant is fed into an inlet at the top of one 
end of the insert and the cell are centrifugally separated from the media. Clarified 
supernatant exists from an outlet at the top of the other end and cell concentrate is 
discharged from an outlet at the bottom of the insert (Fig. 1.13). Centritech Lab III 
centrifuge provides a relatively low-shear condition for cell separation compared with other 










































Fig. 1.13 The principle of cell separation in Centritech Lab III centrifuge Separation 
takes place in a pre-sterilized insert. Separation cycle: cells are separated under low g-forces 
while supernatant is continuously collected. Isolation cycle: concentrated cells are isolated 
by inflating a sealed air barrier which lays behind the separation insert cutting off the feed 
from the concentrated cells. Discharge cycle: concentrated cells (yellow) are discharged via 











1.6.3 ATF system 
Recently, an alternating tangential flow (ATF) system was utilized as a cell 
retention device. The ATF system from Refine Technology is the newest perfusion device 
using hollow fiber filter for cell separation from the spent medium (Crowley et al., 2012; 
Shevitz, 2003). The ATF System provides an efficient means for fractionating a mixture or 
suspension of cells, molecules or other particulates. ATF is a patented system with flow 
pattern of changing tangential flow through a filter that results in a more efficient filtration 
process.  
The ATF system consists of the controller, pump, housing, filtration device, and 
joint assembly (connects the housing to the vessel) (Fig. 1.14). The pump is partitioned by 
a medical grade flexible diaphragm into two compartments, an Air (A) side and Liquid (L) 
side. Any change in volume in compartment A will cause an equivalent but opposite 
change of volume in the L compartment. Controlled flow of filtered air to or from 
compartment A provides the driving energy for the corresponding, but inverse, liquid flow 
in other compartment B, or between a vessel and ATF Pump through a filter module. In the 
ATF system, cells are separated by repeated and rapid flow between the bioreactor and the 
hollow fiber filter due to the action of a diaphragm pump (Fig. 1.15).  
The main features of the ATF system are self-cleaning and back-flushing action 
by a diaphragm pump (Fig. 1.16). The repeated and rapid flow between hollow fiber inlets 
and bioreactor by a diaphragm pump inhibits the blockage of hollow fiber inlets. In 
addition, back-flushing flow created by changing transmembrane pressure protects the 
hollow fiber filter from biofilm formation on its surface. These two main actions allow 
high cell density culture and extended perfusion time in ATF perfusion culture (Bonham-









































Fig. 1.16 The principle of diaphragm pump Pressure cycle - A Pressurizes by inward 
flow of air = Medium is expelled from L, through the HF Filter, to Vessel. 2. Exhaust cycle 
- A Exhausts by expulsion of air = L Expands by inflow of medium, through the Filter, 









1.7 The scope of thesis 
The first purpose of this thesis is to investigate the reasons for the low FVIII:C 
recovery yield in the ATF perfusion culture. Three different perfusion cultures were 
performed to determine which of the three cell retention systems is the most suitable for 
producing BDD-rhFVIII co-expressed with vWF. Spin-filter, Centritech Lab III system, 
and ATF system were evaluated for their use as a perfusion device. Unexpectedly, it was 
found that the FVIII:C recovery yield is significantly low in only the ATF perfusion culture 
in the first study. 
In filtration-based perfusion, such as ATF perfusion, the retention of the target 
protein inside the bioreactor due to a filter fouling is an inherent problem. Filter fouling 
occurs mainly because of the deposition of cell debris and nucleic acids in the perfusion 
culture of mammalian cells (Mercille et al., 1994).  
Although the ATF system is designed to minimize filter fouling by diaphragm 
pump action (Fig. 1.16), fouling problems were also observed in ATF perfusion culture. 
The concentration difference of high molecular weight antibody across the membrane 
surface was observed in a hollow fiber bioreactor, although a back-flush was applied, as in 
the ATF system. The retention rate was up to 20% (Hiller et al., 1993). Others reported that 
up to approximately 60% of the produced antibody was retained by hollow fiber filter in 
ATF perfusion culture (Clincke et al., 2013).  
However, such a low yield of the target protein observed in the first study has not 
been reported during the production of other therapeutic proteins and antibodies in ATF 
perfusion cultures. Therefore, the possible factors that may be responsible for the low 
FVIII:C recovery yield was studied. Especially, the relationship between TMP across the 
hollow fiber filter membrane and FVIII:C recovery yield was examined. It was found out 
that transmembrane pressure has a great effect on the FVIII yield in ATF perfusion culture. 
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It was described in Chapter III. 
The second purpose of this thesis is to develop a modified harvest system in 
order to increase the FVIII yield in ATF perfusion culture, which was described in Chapter 
IV. The system developed in this thesis consists of a check valve, pinch valve and timer 
(Fig. 4.1). The main idea is to increase the TMP across hollow fiber filter membrane, 
which was achieved by the use of the check valve. In Chapter V, the performance of the 
modified harvest system was compared with the peristaltic pump harvest system and 
examined the relationship between the enhanced FVIII:C recovery yield and the TMP 
across the hollow fiber membrane. It was reported that the modified harvest system 
achieved the higher TMP compared with a peristaltic pump harvest system. It was also 
demonstrated that the modified harvest system could be successfully applied to ATF 
perfusion culture instead of a peristaltic pump. In conclusion, the modified harvest system 
can achieve the enhancement of the concentration and product yield of FVIII:C. 
The modified harvest system developed in this thesis can be applied to ATF 
perfusion culture for the production of other therapeutic proteins. The results of this thesis 





































2.1 Cell line and inoculum preparation  
The cell line used was generated from dihydrofolate reductase (DHFR)-deficient 
Chinese hamster ovary (CHO) cells (DG44; obtained from Dr. L. Chasin). CHO cells were 
transfected with an expression vector encoding B-domain deleted rhFVIII (BDD-rhFVIII). 
Then a vWF expression vector was introduced into the BDD-rhFVIII producing CHO 
cells (Fig. 2.1). The inoculum for the bioreactor culture were produced using Erlenmeyer 
flasks (Corning, USA). Erlenmeyer flasks were maintained at 100 rpm on an orbital shaker 
in a humidified 5% CO2 incubator (Sanyo, Japan) at 34
oC. Both in an Erlenmeyer flask and 
bioreactor, cells were cultured in a CHO DHFR- medium (SAFC biosciences, USA) 
supplemented with glutamine. Cells were passaged twice a week by dilution with fresh 
medium. 
 
2.2 Perfusion culture  
Three different cell retention devices, a Centritech Lab III centrifuge (Carr 
Centritech, USA), a spin-filter (New Brunswick Scientific, NJ), and an ATF-4 system 
(Refine Technology, NJ) were used for perfusion culture. Perfusion cultures were 
performed in a 5 L BioFlo 310 bioreactor (New Brunswick Scientific, NJ) with a working 
volume of 3L.  
The ATF-4 system used was controlled by the C24-4 version 1.01 controller 
from Refine Technology. A polyether sulfone (PES) hollow fiber filter cartridge (Refine 
Technology, NJ) for ATF-4 system with a 0.2 mm (F4:RF-02PES, Refine Technology) or 
0.5 mm (F4:RF-05PES, Refine Technology) pore size was used for ATF perfusion.  
A Centritech Lab III centrifuge was operated in the intermittent pump mode for 
perfusion. Operating parameters such as separation time, discharge time, separation speed, 








Fig. 2.1 Establishment of the production cell line co-expressing FVIII and vWF the 
BDD-FVIII expression vector (pCMV-BDD FVIII) was introduced into DG44 CHO cell 
line with a dihydrofolate reductase (DHFR) gene. After methotrexate (MTX) amplification, 
the FVIII producing CHO cell line resistant to 5mM MTX was selected. Then, the vWF 












waiting time, and number of cycles were set at 6 sec, 5 sec, 38 rpm, 30 rpm, 800 rpm, 46 
sec, 37 sec, 60 sec, 40 min, and 39 cycles, respectively, at a perfusion rate of 2 vvd (volume 
of medium perfused per bioreactor volume per day). 
An internal spin-filter (#M1273-3202, New Brunswick Scientific, NJ) was used 
with a BioFlo 310 bioreactor for perfusion culture. The spin-filter module had a filter 
screen with 12-14 mm mesh size and a low shear marine blade impeller. 
The same culture parameters, as described below, were used for the three 
perfusion cultures. The seed cells grown in Erlenmeyer flasks were inoculated in the 
BioFlo 310 bioreactor. The bioreactor was equipped with a dissolved oxygen (DO) probe, 
pH probe, and temperature probe. Culture temperature, DO, pH, and agitation speed were 
controlled automatically and monitored using BioCommand software (New Brunswick 
Scientific, JN) and a personal computer.  
The DO concentration was kept at approximately 50% of air saturation by 
adjusting the air/O2 ratio of the inlet gas. The agitation speed was also varied between 100 
to 150 rpm to maintain the DO level. The pH was kept at a constant value of 7.0 by adding 
a 7.5% (w/v) NaHCO3 solution or adjusting the CO2 ratio of the inlet gas. The culture 
temperature was maintained at 34oC.  
Approximately 30 mL of the samples were taken once every day after the 
perfusion was started. After centrifugation for cell separation, an aliquot of the sample was 
immediately frozen at -80oC for further analysis.  
Glucose, lactate, glutamine, and ammonia concentrations were analyzed off-line 
by a YSI 7100 multiparameter bioanalytical system (YSI Inc., Yellow Springs, OH).  
Cell density and viability were measured by an automated trypan blue cell 
density examination system (Cedex, Innovatis GmbH, Germany). Viable cell density was 
stably maintained by cell bleeds. The perfusion rate was controlled by adding fresh 
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medium and withdrawing an equal volume of clarified supernatant with a peristaltic pump.  
Perfusion was started when the residual glucose level was below 1 g/L. The 
perfusion rate was adjusted in order to maintain glucose level above 1 g/L. A 20 L BioEaze 
bag (SAFC biosciences, USA) was used as a harvest bag. The harvest bag was placed in a 
4oC refrigerator until replacement with a new harvest bag.  
 
2.3 Dead-end filtration  
The harvested supernatant from both Centritech Lab III and spin-filter perfusion 
was filtered by a Millipak 200 filter (Merck Millipore, USA) with 0.2 mm pores. Before 
first use, the filter was wetted out by flowing distilled deionized water with a peristaltic 
pump. After filtration of 5 L supernatant, the FVIII:C in the feed sample and filtrate was 
measured by a one-stage clotting assay. 
 
2.4 Storage and surface adsorption experiments  
The stability of FVIII was assessed at three different temperatures: 4oC, -20oC 
and -80oC. Centrifugation was performed for 4min at 3000rpm using Centrifuge 5810R 
(Eppendorf, Germany) to clarify the supernatant from the ATF perfusion culture. The 
clarified supernatant containing FVIII was stored in triplicate 1 mL aliquots in 
polypropylene tubes at each temperature. The FVIII:C was measured at 24h after storage. 
The adsorption experiment was performed for two FVIII activities at 4oC. The 
FVIII activities of the high- and low-activity preparation were 2.1 AU and 0.115 AU, 
respectively. These preparations were obtained from the ATF perfusion culture. Each 
duplicate 12 L sample was stored at 4oC in the 20 L BioEaze bag (SAFC biosciences, 
USA), which was used as a harvest bag. The surface material of the BioEaze bag is a single 
layer of Dow ATTANETM, an ultra-low density polyethylene (ULDPE). The FVIII:C in the 
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supernatant was measured at times 0, 3, 6, 18, and 24h, respectively. 
 
2.5 Controlled TMP experiment  
A KrosFlo Research IIi tangential flow filtration system (Fig. 2.2) (Spectrum 
Laboratories, Inc., CA) was utilized to measure the transmembrane pressure across the 
MiniKros plus hollow fiber filter module (Spectrum Laboratories, Inc., CA) with a 0.2 mm 
pore size and 3100 cm2 surface area. Polysulfone pressure transducers were connected to 
the inlet, the outlet, and the permeate port of the MiniKros plus hollow fiber filter module.  
The culture supernatant from the Centritech Lab III perfusion was circulated 
through a MiniKros plus hollow fiber filter thru the built-in peristaltic pump of a KrosFlo 
Research IIi system. The TMP was controlled by the peristaltic pump speed and the 
KrosFlo automatic backpressure valve according to the manufacturer’s instructions. 
Pressure changes at each point were monitored simultaneously using KF COMM software 
from Spectrum Laboratories. The TMP was calculated by using the following formula: 
TMP = (Inlet pressure + Outlet pressure)/2-Permeate pressure 
 
2.6 Perfusion culture with a modified harvest system and a peristaltic pump system 
The ATF-4 system and C-24 controller (both from Refine Technology) were used 
for perfusion culture. The seed cells were inoculated in a BioFlo 310 bioreactor (New 
Brunswick Scientific) at a starting concentration of approximately 5x105 cells/mL. The 
working volume was 3 L. Hollow fiber modules (Refine Technology) with a 0.2 mm pore 
size was used. ATF flow rate was 3 L/min. One perfusion run (ATF no. 1) was data from 
our previous study (Kim et al., manuscript submitted) using a peristaltic pump for harvest. 





Fig. 2.2 KrosFlo Research IIi system (source: www.spectrumlabs.com) A: 
backpressure valve, B: pressure transducer, C: hollow fiber filter, D: peristaltic pump, E: 












system. Data from these two runs were averaged and are denoted ATF no. 2.  
In a peristaltic pump harvest system, the perfusion rate was controlled as follows. 
The supernatant filtered through a hollow fiber filter was drawn into a harvest bag at a 
constant rate by the built-in peristaltic pump of the aforementioned bioreactor. Fresh 
medium was automatically added by the peristaltic pump, which was actuated by the 
weight change of the bioreactor vessel measured by a load cell until the vessel weight is 
increased to the set-point.  
The system function was as follows. First, fresh medium was added to the 
bioreactor vessel at a constant rate by the built-in peristaltic pump. If the vessel weight 
increased to the set-point, the load cell provided an off signal to the timer connected to the 
pinch valve. The timer allowed the pinch valve to open for one minute, even though the 
vessel weight had decreased to below the set-point. The controller then provided an on 
signal to the pinch valve. The above cycle was repeated, making it possible to control the 
perfusion rate. 
Daily samples were taken from the bioreactor for analysis. After centrifugation, 
the samples were immediately frozen at -80oC for further analysis. The viable cell density 
and viability were measured by trypan blue staining using Cedex (Innovatis GmbH, 
Germany). 
 
2.7 Measurement of TMP during the operation of ATF system 
The bioreactor vessel was filled with deionized water instead of cells and 
medium for TMP measurement experiment under the cell-free condition. A KrosFlo 
Research IIi system (Spectrum Laboratories, CA) was used to measure TMP across the 0.2 
mm pore size hollow fiber filter (Refine Technology).  
As shown in Fig. 2.3, three pressure transducers were connected to the bioreactor 
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connection port, the second chamber of a diaphragm pump and the harvest port of the 
hollow fiber filter module. Pressure measurement at each point was performed using KF 
COMM software (Spectrum Laboratories).  
TMP was automatically calculated as using the following formula: (Inlet pressure 
at the bioreactor connection port + Outlet pressure at the second chamber of a diaphragm 
pump) / 2 – Permeate pressure at the harvest port. 
  
2.8 FVIII:C and antigen assay  
FVIII:C was measured by a one-stage clotting assay with an ACL TOP 500 CTS 
(Instrumentation Laboratory, USA) according to the manufacturer's instructions and as per 
the Fourth International WHO standard. FVIII antigen content (FVIII:Ag, FVIII antigen) 
was quantified by an anti-FVIII light chain sandwich enzyme-linked immunosorbent assay 
(ELISA) using an in-house BDD-rhFVIII antigen as a standard and an in-house ELISA kit. 
 
2.9 vWF antigen assay  
vWF protein content (vWF:Ag, VWF antigen) was quantified by a sandwich 
ELISA, REAADS® von Willebrand factor antigen test kit (Corgenix Inc., Broomfield, CO, 
USA) according to the manufacturer's instructions.  
 
2.10 Statistical analysis  
Data were statistically analyzed by a two-tailed student’s t-test using Microsoft 










Fig. 2.3 TMP measurement during the operation of ATF system Pressure transducers 
















Study of the effect of transmembrane 


















3.1 Cell growth and FVIII production in three different perfusion cultures 
Three different perfusion cultures were performed to compare performance in the 
production of BDD-rhFVIII co-expressed with vWF. Fig. 3.1A shows cell growth 
performance during perfusion culture using the three different devices. 
In the Centritech Lab III perfusion culture, viable cell density was stabilized at an 
average of 3.5x107 cells/mL at a perfusion rate of 2 vvd after day 10. Since the separation 
efficiency rapidly decreased above 4x107 cells/mL, viable cell density was controlled 
below 4x107 cells/mL.  
Viable cell density in the spin-filter perfusion was maintained at an average of 
1.76x107 cells/mL for the culture duration after day 10 at a perfusion rate of 1.5 vvd in 
order to avoid filter clogging and extend culture duration.  
In the ATF perfusion culture, viable cell density was stabilized at an average of 
5.02x107 cells/mL at a perfusion rate of 2 vvd. However, after day 27 viable cell density 
was increased to between 8 and 10x107 cells/mL in order to evaluate the performance of 
the ATF system in a very high cell density.  
The FVIII:C in the bioreactor varied between 0.1 to 0.2 AU in both the 
Centritech Lab III and spin-filter perfusion cultures (Fig. 3.1B). The average value of 
FVIII:C in the bioreactor was 0.138 AU and 0.131 AU in the Centritech Lab III and spin-
filter perfusion cultures, respectively. The average FVIII:C in the harvest after cell density 
stabilization was 0.13 AU and 0.17 AU in the Centritech Lab III and spin-filter perfusion 
cultures, respectively (Fig. 3.1D). As shown in Fig. 3.1C, these two perfusion cultures 
showed more than a 70% FVIII:C recovery yield. 
As shown in Fig. 3.1B-D, the FVIII production profile in the ATF perfusion 
culture was significantly different from the other two perfusion cultures. The FVIII:C in the 
bioreactor was rapidly increased up to 1.05 AU according to an increase in culture time 
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(Fig. 3.1B). In contrast, FVIII:C in the harvest was continuously decreased with an increase 
in the culture time, and FVIII:C in the final harvest bag was 0.024AU (Fig 3.1D). At the 
beginning of the ATF perfusion culture, the FVIII:C recovery yield was 71.2% (Fig 3.1C). 
This yield at the start of perfusion culture was almost equivalent to that in the Centritech 
Lab III or spin-filter perfusion cultures. However, FVIII:C recovery yield rapidly decreased 
over the culture time. The average FVIII:C recovery yield was only 8.2% in the ATF 
perfusion culture. This yield was 10-fold lower than that in the other two perfusion cultures. 
Such a low yield of the interest protein as well as FVIII in ATF perfusion culture, has not 
been previously reported. 
 
3.2 Effect of storage temperature on FVIII:C recovery yield  
Since the FVIII molecule is an unstable protein in a CHO cell culture supernatant 
as described previously (Kaufman et al., 1988), there is a strong possibility that inactivation 
of FVIII may occur. Therefore, a FVIII storage stability test was performed to check 
whether FVIII inactivation occurs during storage in the harvest bag. A polypropylene tube 
was utilized as a storage container in order to exclude the problem of surface adsorption of 
FVIII molecules (McLeod et al., 2000). When the perfusion rate was 4vvd, the harvest bag 
was replaced with a new harvest bag after every 24h. Therefore, if the FVIII:C had not 
decreased after 24h storage, it was obvious that the inactivation of FVIII was not a 
dominant factor in the reduction of the FVIII:C recovery yield.  
As shown in Table 3.1, FVIII:C recovery after 24h storage at 4oC was 92.8%. A 
slightly lower FVIII:C recovery was noted in the other two storage conditions, 86.9% for -
20oC (*P < 0.05) and 90.9% for -80oC. Hence, this result implies that although inactivation 
of FVIII may occur during storage in the harvest bag, it is not a dominant factor that affects 





Fig. 3.1 Comparison of three cell retention devices. Cell growth performance (A), FVIII:C 
in the bioreactor (B), FVIII:C in harvest (C), and FVIII:C recovery yield (D). The FVIII:C 
in the bioreactor was calculated based on the average of FVIII:C measured in daily 
samples taken from the bioreactor until the next harvest. Error bars represent standard 
deviations. Number (n) of separate experiments: n=3 (Centritech Lab III), n=2 (spin-filter) 








Table 3.1 Comparison of FVIII:C and recovery after storage at various temperatures 
Storage  
temperatures 
Time = 0 4oC -20oC -80oC 
FVIII:C (AU)a 2.03 ± 0.13 1.88 ± 0.09 1.76 ± 0.18 1.84 ± 0.11 
Recovery (%)b 100 92.8 86.9* 90.9 
a Mean ± SD (n=3), b Recovery (%) were calculated based on average FVIII:C. AU 











3.3 Effect of the adsorption of FVIII molecule onto the container surface on FVIII:C 
recovery yield  
 McLeod et al. (2000) previously reported the loss of recombinant FVIII:C during 
storage in polyvinyl chloride (PVC) containers, but not in polypropylene syringes. They 
obtained a 41.9% and a 43.7% FVIII:C recovery in undiluted (146 IU/mL) and diluted (10 
IU/mL) samples after 48h of storage in a PVC bag at room temperature. However, only 
1.8% FVIII:C was obtained in FVIII diluted to 2IU/mL. Hence, in their study, they found 
that the loss of FVIII:C was due to the adsorption of FVIII:Ag onto the surface of PVC.  
Their result suggests that the adsorption of FVIII:Ag can also be an important 
cause for low FVIII:C recovery yield in the ATF perfusion culture. Therefore, FVIII:C 
recovery yield after 24h storage at 4oC in the harvest bag was measured to check whether 
the loss of FVIII:C was due to FVIII:Ag adsorption onto the surface of the harvest bag.  
When the perfusion rate was 4vvd, the harvest bag was replaced with a new 
harvest bag after every 24h. Therefore, if the FVIII:C had not decreased after 24h storage, 
it was obvious that the adsorption of FVIII was not a dominant factor in the reduction of 
the FVIII:C recovery yield. 
Table 3.2 shows that the recovery of FVIII:C was 89% for 2.1 AU and 95.7% for 
0.115 AU after 24h. This loss of activity could be due to the inactivation of FVIII during 
storage. Therefore, it was concluded that the loss of FVIII:C shown in Table 3.2 might be 
mostly due to the inactivation of FVIII during storage. It was also concluded that the 
adsorption of FVIII:Ag onto the surface of the harvest bag was not a very significant cause.  
The results of Table 3.1 and Table 3.2 evidently showed that the adsorption of 
FVIII:Ag onto the surface of the harvest bag and inactivation of FVIII were not the main 







Table 3.2 Variation in FVIII:C and recovery over time during storage in the harvest bag  
 
Storage duration (h) 
FVIII:C (AU) 
High activity Low activity 
0 2.10 ± 0.04 (100) 0.115 ± 0.009 (100) 
3 2.05 ± 0.05 (97.6) 0.117 ± 0.003 (102) 
6 1.91 ± 0.06 (90.9) 0.109 ± 0.012 (94.8) 
18 1.78 ± 0.12 (84.8) 0.106 ± 0.006 (92.2) 
24 1.87 ± 0.08 (89.0) 0.110 ± 0.009 (95.7) 
 
The values in parentheses indicate the FVIII:C recovery calculated based on average 










3.4 Effect of the retention of FVIII:Ag by the hollow fiber filter on FVIII:C recovery 
yield  
In this study, it was assumed that three possible mechanisms could lead to a very 
low FVIII:C recovery yield in ATF perfusion culture. In the previous section, two possible 
mechanisms such as the inactivation and the adsorption of FVIII were investigated. It was 
also demonstrated that those factors were not a dominant factor of a low FVIII:C recovery 
yield in ATF perfusion culture. 
The last possible cause of low FVIII:C recovery yield was the retention of 
FVIII:Ag by the hollow fiber filter membrane. Since fouling of the hollow fiber filter is an 
intrinsic problem of a membrane-based perfusion culture (Mercille et al., 1994), the 
possibility of a reduction of yield due to fouling obviously exists even in an ATF perfusion 
culture.  
Since most of the secreted FVIII exists as a FVIII/vWF complex in the 
supernatant of a CHO cell culture (Kaufman and Pipe, 1999; Wise et al., 1991), a reduction 
in the amount of FVIII:Ag will be accompanied by a decrease in the amount of vWF:Ag. 
Moreover, the loss of co-secreted vWF:Ag will occur at the same rate, because vWF has 
the capacity to form a complex with FVIII at a constant ratio of 1:1 ~ 1:70 as described 
previously (Kaufman and Pipe, 1999; Vlot et al., 1995). Therefore, FVIII:Ag and vWF:Ag 
assays was performed to assess the possibility of retention of FVIII:Ag due to the filtration 
action of ATF hollow fiber filter. 
As shown in Table 3.3, the FVIII:C recovery yield at day 35 of ATF perfusion 
culture was 3.13%. The vWF yield by vWF:Ag ELISA and the FVIII:Ag yield by 
FVIII:Ag ELISA was 2.99% and 2.50%, respectively. The decreasing ratio of FVIII:Ag 
yield was quite similar to the ratio of the reduction of vWF:Ag yield. It was also very 






Table 3.3 Comparison of FVIII:C, FVIII:Ag, and VWF:Ag yield at day 35 in ATF 
perfusion culture 
 
 Bioreactor (AU) Harvest (AU) Yield (%) 
FVIII:C 0.775 0.025 3.13 
FVIII:Ag 0.959 0.024 2.50 
VWF:Ag 0.885 0.026 2.99 
 












Since inactivation and protein loss by surface adsorption was shown to not be 
dominant factors in low FVIII:C recovery yield, these results clearly indicate that the 
retention of FVIII:Ag by the hollow fiber filter was the main cause of the reduction of 
FVIII:C recovery yield. Furthermore, these results also suggest that the increase in FVIII:C 
in the bioreactor during ATF perfusion culture was due to the accumulation of retained 
FVIII:Ag (Fig. 3.1B). 
 
3.5 Retention of FVIII:Ag by dead-end filtration  
The culture supernatant collected in the harvest bag in both the Centritech Lab III 
and spin-filter perfusion cultures must be clarified using a filter with a pore size smaller 
than 0.2 mm in order to proceed to the purification processes. Therefore, the actual FVIII:C 
recovery yield should be calculated after filtration of the harvest. Fig. 3.2 shows the 
FVIII:C recovery yield after filtration using a membrane with 0.2 mm pores for 
supernatants from both perfusion cultures. After membrane filtration, a decrease in FVIII:C 
recovery yield was observed. The FVIII:C recovery yield was 63.7% for the Centritech 
Lab III and 52.8% for the spin-filter. Although these yields were significantly higher than 
that in the ATF perfusion culture, this also provided clear evidence of the retention of 
FVIII:Ag by filtration action.  
 
3.6 Effect of the pore size of hollow fiber filter on FVIII:C recovery yield  
ATF perfusion culture was performed using a hollow fiber filter with 0.5 mm 
pores in order to evaluate the effect of the increased pore size on FVIII:C recovery yield. 
The FVIII:C recovery yield with a 0.5 mm pore size was 53.4% in the first harvest, 20.1% 
in the second harvest, and 17.8% in the third harvest, (Fig. 3.3B). FVIII:C recovery yields 






Fig. 3.2 Comparison of FVIII:C between samples before and after dead-end filtration. AU 
indicates arbitrary unit. Error bars represent standard deviations with n=3. *P < 0.05 (two-










with 0.2 mm pores gave 57.4%, 21.1%, and 16.9%, respectively, as shown in Fig. 3.3A.  
The FVIII:C recovery yield of both perfusion cultures was very similar. In 
addition, a similar decreasing trend in FVIII:C recovery yield over the culture time was 
observed in both perfusion cultures. Consequently, it is obvious that increasing the pore 
size of the hollow fiber filter in the ATF perfusion culture is not an exact solution for 
increasing FVIII:C recovery yield. 
 
 
3.7 Effect of TMP on FVIII:C recovery yield, FVIII:Ag yield, and vWF:Ag yield  
A controlled TMP experiment with a hollow fiber filter was performed in order 
to evaluate the increased TMP on the FVIII:C recovery yield, FVIII:Ag yield, and vWF:Ag 
yield. The yields after hollow fiber filtration under controlled TMP are shown in Fig. 3.4. 
FVIII:C recovery yield, FVIII:Ag yield, and vWF:Ag yield were 93.7%, 91.9% and 89.2%, 
respectively, on applying TMP of less than 10 psi (the average TMP was 2.83 psi).  
However, these yields were rather significantly decreased when a TMP of more 
than 10 psi was applied. At 10 psi TMP, FVIII:C recovery yield, FVIII:Ag yield, and 
vWF:Ag yield decreased to 34.6%, 33.6%, and 35.9%, respectively. At above 10 psi, data 
showed that these yields, FVIII:C recovery yield, FVIII:Ag yield, and vWF:Ag yield, 
decreased to between 16~20%. These results suggest that the control of TMP under 10 psi 
can be a good way of enhancing FVIII:C by reducing the retention of FVIII:Ag in an ATF 
perfusion culture. However, further studies are needed to elucidate the mechanism by 
which the FVIII yield is decreased under an increased TMP of more than 10 psi. 
In addition to fouling of the hollow fiber filter, another important factor to be 





Fig. 3.3 Cell growth and FVIII production profile in an ATF perfusion using a hollow fiber 










Fig. 3.4 FVIII:C, FVIII:Ag concentration and vWF:Ag concentration after hollow fiber 
filtration under controlled transmembrane pressure. The measured transmembrane pressure 
is indicated in the X-axis. BF means before filtration. AU indicates arbitrary unit. Psig is 
the abbreviation of pounds per square inch gage. Error bars represent standard deviations 









Fig. 3.5 Schematic model using actual AFM images of vWF illustrating shear-induced 
conformational changes in vWF under aqueous conditions Under negligible shear, 
vwF has a globular conformation. After exposure to a shear stress field of 35 ± 3.5 
dyne/cm2, vWF is observed in extended conformation with molecular length ranging from 




As shown in Fig. 3.5, vWF has a long extended chain conformation after 
exposure a shear stress. It has been reported that the hydrodynamic radius of vWF 
multimer can be increased up to 466 nm under shear stress (Hoyer and Shainoff, 1980; 
Shankaran et al., 2003). Also, it has been reported that the fully stretched vWF multimer 
showed an end-to-end length ranging from 2,300~2,800 nm (Seyfried et al., 2010).  
Thus, it can be hypothesized that the co-expressed vWF in this study may partly 
contribute to the retention of FVIII:Ag due to filtration. However, exact details regarding 
the effect of vWF multimer on the FVIII yield in ATF perfusion have not yet been reported 
upon. The current experimental results do not enable further conclusions to be drawn to 
prove our hypothesis. Thus, further studies are needed in order to better understand the 




In this study, it was reported the observation that FVIII:C recovery yield in an 
ATF perfusion culture was considerably lower, compared with two other perfusion systems 
such as a spin-filter and Centritech Lab III centrifuge. The results of this study successfully 
demonstrated that the low FVIII:C recovery yield in an ATF perfusion culture was not due 
to the inactivation or surface adsorption of FVIII molecules, but due to the retention of 
FVIII molecules by hollow fiber filtration.  
Controlled TMP below 10 psi resulted in remarkable enhancement of FVIII yield 
in hollow fiber filtration. These observations suggest that TMP across a hollow fiber filter 
is a key factor in increasing the product yield of FVIII in an ATF perfusion culture.  
However, the FVIII yield was rather decreased under an increased TMP of more 
than 10 psi. It was also suggested that the reduction of the product yield of FVIII above 10 
57 
 
psi might be due to the conformational change of vWF molecule under shear stress.  
Although further studies are needed to develop a precise control method for TMP 
and to determine an optimal TMP, the findings of this study can be applied to improving 

















































4.1 Theoretical background 
Filtration is a pressure-driven membrane process by which target proteins 
(solutes) are separated from the supernatant (solvent). In case of a pure solvent flowing 
under a laminar flow condition, the relationship between the permeate flux and the 







=            (4-1) 
where J is the flux (volumetric rate per unit area), PD is the transmembrane pressure, 
m is the solvent viscosity, and mR is the membrane resistance. 
The filtration process in the presence of a solute is described by the following equation 










      (4-2) 
where pD is the difference in osmotic pressure across membrane and sR is the total 
deposition of solute onto the membrane surface. The m sR R+ represents the total 
resistance. 
 According to these equations (4-1 and 4-2), the permeate flux is directly 
proportional to the TMP when other parameters are the same. It was reported that the yield 
of target proteins is affected by the TMP (Ahmad, 2012). Hirasaki et al. (Hirasaki et al., 
1995) also showed that the permeability of two kinds of DNA with different molecular 
weights, lDNA (MW = 3X107) and Bacillus sp. DNA (average MW = 1X108) is increased 
when the TMP increased. In chapter III of this study, it was demonstrated that the 
controlled TMP below 10psi resulted in remarkable enhancement of FVIII yield in hollow 
fiber filtration. And it was suggested that the TMP across hollow fiber filter is a key factor 
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to increase the product yield of FVIII in ATF perfusion culture.  
The aim of this chapter is to develop a device in order to increase the TMP across 
hollow fiber filter. The transmembrane pressure across hollow fiber filter of ATF system is 







= -             (4-3) 
where inP  is the inlet pressure at the bioreactor connection port, outP is the outlet 
pressure at the second chamber of a diaphragm pump, and permP is the permeate pressure 
at the harvest port. 
 According to the equation 4-3, there are two methods to increase the TMP. One is 
to increase inP  and outP . Unfortunately, inP  and outP  is a function of the diaphragm 
pump speed which directly affects cell viability and cell growth negatively. inP  and 
outP could be controlled by squeeze the connection tubing between the bioreactor and the 
bioreactor connection port of ATF. However, this method results in the increase of shear 
stress which also might affect cell viability negatively. Thus, there are some limitations to 
increase the TMP by increasing inP  or outP . The other is to decrease permP .  However, 
it is difficult to decrease permP in the peristaltic harvest system as described in Chapter IV. 
4.5. Thus, it was strongly required to develop an alternating harvest system eliminating the 
need of a peristaltic pump. In latter part of this chapter, the design and the principle of the 
novel harvest system was described. The application of the system was described in 
Chapter V. 
 
4.2 Peristaltic pump harvest system 
Peristaltic pumps have been widely used for many years in scientific, medical 
and industrial applications whereby a fluid is delivered through a single compressible tube 
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at a controlled rate. The pumping principle is based on the peristaltic motion of a peristaltic 
pump. The Webster’s definition of peristalsis is “the successive waves of involuntary 
contraction passing along the walls of a hollow muscular structure (as the esophagus or 
intestine) and forcing the contents onward” Peristalsis is a series of wave-like muscle 
contractions that moves food to different processing stations in the digestive tract. 
Peristaltic pump is composed of three parts: drive, pump head and tube. Typically, 
the pump head of peristaltic pump has a rotor with several rollers. As the rotor turns, the 
flexible tubing is squeezed at each roller location. And then the flexible tubing is released. 
The alternating pattern of squeezing and releasing the flexible tubing moves the fluid 
through the peristaltic pump. The part of tubing under compression by roller of a peristaltic 
pump is always in a closed state.  
Peristaltic pumps transfer fluids successfully in industries such as food 
processing, pharmaceutical manufacturing, and chemical processing, as well as in 
laboratory research, agriculture, and water treatment. The most important advantage of 
peristaltic pumps is their use of tubing as the pump chamber. The fluid is inside the tubing 
and does not contaminate the pump, nor does the tubing contaminate the fluid. The biggest 
advantage of the use of peristaltic pumps is to maintain fluid aseptic condition. Fluid does 
not contact any part of the pump except inside the tubing. In the whole process of the 
pharmaceutical industry, the aseptic condition is a basic requirement of the general. The 
peristaltic pump with high flow precision can satisfy the transmission of various 
quantitative pharmaceutical process requirements. In the process of production of raw 
medicine synthesis, extraction and culture, peristaltic pumps are used to add all kinds of 
acids, solvents, alkalis, nutrient solution, buffer solution and raw materials and are used to 
sampling and collection.  
A typical application is the application of peristaltic pump in bioreactor for 
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microbial and mammalian cell culture. Peristaltic pumps are used to add cell culture 
medium, feed solution, and base. Peristaltic pumps are also used to sampling. Especially in 
perfusion culture, two peristaltic pumps are mainly and generally used for the addition of 
fresh medium and/or the withdrawal of spent medium, i.e. perfusion rate control. Peristaltic 
pumping has been described for perfusion rate control in the application of the ATF system 
to perfusion culture (Clincke et al., 2013). 
 
4.3 TMP in the peristaltic harvest system 
In chapter III, it was demonstrated that the controlled TMP below 10psi resulted 
in remarkable enhancement of FVIII yield in hollow fiber filtration. And it was suggested 
that the TMP across hollow fiber filter is a key factor to increase the product yield of FVIII 
in ATF perfusion culture. Therefore, it was necessary that the transmembrane pressure 
across hollow fiber filter should be measured during the operation of ATF system with a 
peristaltic pump harvest system.  
Fig. 4.1 shows the time profile of transmembrane pressure during on time and off 
time in the peristaltic harvest system. The TMP profile shows a somewhat different pattern 
over cycles. It was thought that this result might be due to the resolution problem of the 
recording software used in this study. The minimum data collection period of the recording 
software is 1 second. ‘1 second’ does not seem to be enough time to collect enough data to 
show a precise TMP profile. If higher-resolution recording software were used to collect 
data, we believe, more similar and repeating TMP profiles could be obtained. 
As shown in Fig. 4.1, it is obvious that there was a marginal difference between 
the time profiles of TMP. Even in the peristaltic pump on time, the TMP did not increased 
unexpectedly. The average TMP and the average peak TMP in the peristaltic pump harvest 
























Fig. 4.1 Time profile of TMP during the Peristaltic pump on-time (A) and off-time 
(B) Transmembrane pressure (thick solid line), inlet pressure (solid line), outlet pressure 
(gray line) and permeate pressure (dashed line). Psig is the abbreviation of pounds per 
square inch gage. 
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4.4 Effect of the pump speed on TMP in the peristaltic harvest system 
The time profile of TMP according to the peristaltic pump speed was measured 
because the increase of the pump speed can affect the permeate pressure by increasing the 
amount of filtrate flowed into a harvest bag by the suction of the peristaltic pump.  
As shown in Fig. 4.2, the measured peak of TMP was 0.157 psig for 5 rpm, 
0.143 psig for 15 rpm, 0.158 psig for 30 rpm, and 0.160 psig for 50 rpm, on average. The 
measured peak of permeate pressure was 2.17 psig for 5 rpm, 2.16 psig for 15 rpm, 2.18 
psig for 30 rpm, and 2.19 psig for 50 rpm on average. The pump speed of Fig. 4.1 is 14.5 
rpm.  
As a result, increasing the suction speed of the peristaltic pump could not 
increase the TMP. Since the increase of the permeate flux is proportional to the increase of 
TMP, an increase of peristaltic pump speed (i.e. the suction speed) would not increase the 
permeate flux. In conclusion, the FVIII yield could not be increased by increasing the 
peristaltic pump speed. 
 
4.5 Importance of the occlusion of the silicone tubing in the peristaltic pump harvest 
system 
Typically, a peristaltic pump has a rotor with several rollers. The flexible tubing is 
squeezed at each roller location. As the rotor turns, the part of tubing under compression by 
roller of a peristaltic pump is always in a closed state. In other words, the harvest tube is 
always occluded by a peristaltic pump. In most cases, even though in ATF perfusion 
culture, this occluded state is not an important consideration, since the size of the secreted 
proteins is small enough to pass through the hollow fiber filter in the peristaltic harvest 
system as reported in Clincke et al. (2011). 
However, if the size of the target protein is as large as the pore size of hollow 
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fiber filter, the situation is totally different. In high cell density perfusion culture, cells as 
well as cell debris could block membrane pores partially. And although the less formation 
of biofilm is the main advantage of ATF system, biofilm forms in some degree at high cell 
density culture. Due to these two reasons, the effective pore size of hollow fiber filter could 
be decreased. Thus, if the molecular size of the target proteins is large enough to have 
difficulties to pass through the pore of hollow fiber filter, the occlusion of the harvest line 
could be an important issue.  
As described previous section, the increase of TMP is a little difficult by 
increasing inP  or outP . Moreover, the increase of TMP by decreasing permP  is also 
highly difficult due to the lasting occlusion of the harvest line in the peristaltic pump 
harvest system. This is the reason to develop a new harvest system as an alternating of a 
peristaltic pump in ATF perfusion culture. 
 
4.6 Design of the modified harvest system  
As described in 4.1 of Chapter IV, the TMP is highly important in the FVIII yield 
in ATF perfusion culture. It can be assumed that if the TMP during the pressure cycle can 
be increased and maintained positive value, the FVIII yield could be increased. Based on 
this assumption, the modified harvest system composed of a check valve, a pinch valve 
(Fig. 4.3-7) and a timer was developed.  
In the system, the critical point is to minimize the permeate pressure or 
backpressure on the filtrate side and to maintain the positive TMP during the pressure cycle. 
To achieve these purpose, three key components such as a check valve, a pinch valve and a 






























Fig. 4.2 Measurement of average peak TMP and average peak Pperm. TMP: 
transmembrane pressure, Pperm: permeate pressure. Psig is the abbreviation of pounds per 









4.6.1 Check valve 
The check valve (code no. 418, Kartell, Italy) as shown in Fig. 4.3 is a non-return 
valve or one-way valve, which allows the flow of fluid in only one direction. As shown in 
Fig. 4.5-7, the check valve was connected to the harvest port of ATF-4 system (Refine 
Technology, USA) through a 3/16-inch internal diameter silicone tubing (Saint-Gobain, 
France).  
During the pressure cycle, the check valve is always open and allows the filtered 
supernatant to flow smoothly toward the harvest bag. During the exhaust cycle, the check 
valve is closed, blocking the backward flow of the filtered supernatant into inner side of 
hollow fiber filter (Fig 4.4).  
This function of the check valve is essential for ATF action. If the backward flow 
of the filtered supernatant is not prevented by the check valve when the harvest tubing is 
opened, the filtered supernatant can flow back into inner side of the hollow fiber filter 
during the exhaust cycle, and the cell-containing supernatant will not be properly driven 
from the bioreactor vessel to the second chamber of the diaphragm pump.  
As a result, a certain amount of the filtered supernatant can flow back and 
forward between the inner and outer sides of the hollow fiber filter and the cell containing 
supernatant can oscillate between bioreactor and the second chamber of the diaphragm 
pump. Consequently, perfusion culture cannot be properly performed.  
The use of a check valve enables the minimization of permeate pressure in ATF 
perfusion. This characteristic function of a check valve was described in detail in 4.9 and 
4.10 of this chapter. 
 
4.6.2 Pinch valve 
A model RZ-98305-11 pinch valve (Cole-Parmer, USA) was installed after the 
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check valve to open and close silicone tubing between the check valve and the harvest bag 
(Fig. 4.3-7). If only the check valve is used for harvest, all the culture supernatant will be 
continuously filtered out and the vessel will eventually empty. The pinch valve with a timer 
also has an important role in weight-based perfusion rate control with a load cell installed 
under the bioreactor vessel. Since the pinch valve opens and closes the silicone tube in a 
timed fashion, the perfusion rate can be properly controlled. 
 
4.6.3 Timer 
In the modified harvest system, one of the crucial aspects is the use of a timer 
(LE7M, Autronics, USA). The purpose of the use of the timer is to maintain the open state 
of the harvest tube during pressure cycle of pinch valve off-time. The timer was connected 
to the pinch valve and the load cell (Fig. 4.5).  
The timer actuates the pinch valve in accordance with the signal from the load 
cell. If the vessel weight is increased to the set-point, the load cell gives a signal to the timer 
connected to the pinch valve. The timer allows the pinch valve to open for one minute 
(pinch valve off-time). After one minute, the vessel weight is decreased below the set-point 
and the controller confers the close signal to the pinch valve (pinch valve on-time).  
If the pinch valve is directly operated without the timer, the load cell sends on-
and-off signals to the pinch valve repeatedly around the vessel weight set-point. In this 
situation, the harvest tube is quite frequently in the closed state during both pressure cycle 






















4.3 A check valve (A) and a pinch valve (B) The check valve (code no. 418, Kartell, 
Italy) as shown in A is a non-return valve or one-way valve, which allows the flow of fluid 
in only one direction. The pinch valve (model RZ-98305-11, Cole-Parmer, USA) as shown 





4.4 Schematic representation of the operation of a check valve The check valve always 
open and allows the filtered supernatant to flow smoothly toward the harvest bag during 
the pressure cycle. During the exhaust cycle, the check valve is closed, blocking the 






















Fig. 4.6 Schematic view of ATF perfusion system with a modified harvest system at 
















Fig. 4.7 Schematic view of ATF perfusion system with a modified harvest system at 












4.7 Determination of the pinch valve off-time 
The pinch valve off-time is directly related to the control of the perfusion rate in 
ATF perfusion culture. The pinch valve off-time is directly controlled by the timer 
connected to the pinch valve and the load cell. The increase of the pinch valve off-time 
during the pressure time means the increase of the amount of the filtrate flowed into a 
harvest bag (i.e. the harvest volume). The increase of the harvest volume results in the rapid 
change of the bioreactor volume which can affect DO, pH, temperature and cells.  
First of all, the flow rate of the filtrate into a harvest bag was measured in order to 
optimize the duration time of the pinch valve off-time. The flow rate over time was shown 
in Table 4.1. The measured average flow rate per minute was approximately 220mL/min. 
The change of the bioreactor volume for 1 minute was 7.4% of the working volume. This 
amount of volume change did not result in a fluctuation of DO, pH or temperature and did 
not affect cell viability or cell growth. Therefore, 1 minute was chosen as the duration of 
the pinch valve off-time.  
Based on the data of Table 4.1, the cycle was composed of a 1 min of the pinch 
valve off-time and a 79 min of the pinch valve on-time. In total, 18 cycles per day were 
conducted at1vvd. The theoretical volume of the filtrate per day was 3L. The actual volume 
of the filtrate per day was 2.98L. From these data, it was concluded that the perfusion rate 
was successfully controlled by adjusting the on-and off-time of the pinch valve. 
 
4.8 TMP in the modified harvest system 
The TMP across hollow fiber filter was measured during the operation of ATF 
system with the modified harvest system. Fig. 4.8 and Fig. 4.9 shows the time profile of 
TMP during on-and off-time of the modified harvest system. The TMP profile showed also 






Table 4.1 Determination of the pinch valve off-time 
Time (min) Cumulative filtrate volume (mL) Difference (mL) 
1 248.7 ± 3.2 - 
2 472.7 ± 3.1 224.0 
3 690.3 ± 7.5 217.7 
4 921.3 ± 3.2 231.0 
5 1132.7 ± 5.5 211.3 
Average 248.7 ± 3.2 221 












system. It was also thought that this result might be due to the resolution problem of the 
recording software used in this study. 
As shown in Fig. 4.8, the time profile of TMP during the pinch valve on-time 
was quite similar to that during the peristaltic pump on- and off-time according to 
expectation. However, the time profile of TMP during the pinch valve off-time was totally 
different from that of the peristaltic pump harvest system (Fig. 4.9). The permeate pressure 
was dramatically decreased during the pressure cycle. The TMP was also increased and 
maintained a positive value during the pressure cycle. These results demonstrated that the 
permeate pressure was successfully decreased by the use of the pinch valve and the check 
valve. From these data, it can be concluded that the modified harvest system can achieve 
the enhanced FVIII yield through the TMP increase. 
 
4.9 Comparison of the TMP profiles of the peristaltic pump harvest system and of the 
modified harvest system 
The time profile of TMP variation in both the peristaltic pump system and the 
modified harvest system was compared, and is depicted in Fig. 4.10. Since the yield of 
target proteins is affected by the TMP during harvest (Ahmad, 2012; Hirasaki et al., 1995; 
Salgin and Salgin, 2007), the TMP in the pinch valve off-time of the modified harvest 
system was compared with that in the operation time of the peristaltic pump.  
In the peristaltic pump harvest system, TMP was rapidly increased with the start of 
pressure cycle and had its maximum value in the last time of the pressure cycle. During the 
exhaust cycle, the TMP was also rapidly decreased until back flushing by a negative TMP 
occurred (Shevitz, 2003). However, the time profile of TMP variation in the pinch valve 
off-time was significantly different from the peristaltic pump. The TMP was maintained 
positive, regardless of the pressure or the exhaust cycle. TMP fluctuated between 0.22 and 
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0.31 psig. The average TMP and the average peak TMP of three pressure cycles was 0.13 ± 
0.04 psig and 0.16 ± 0.005 psig, respectively, in the peristaltic pump harvest system and 
0.25 ± 0.03 psig and 0.31 ± 0.003 psig, respectively, in the modified harvest system (Fig. 
4.9). The modified system achieved an 89% higher average TMP and a 96% higher peak 
TMP in the pressure cycle (P < 0.001, two-tailed Student’s t-test). As a result, the 
enhancement of the recovery yield of FVIII:C resulted from the increase of TMP.  
As shown in Fig. 4.11, there were significant decreases in the peak permeate 
pressure to 44.8%, peak outlet pressure to 37.5% and peak inlet pressure to 61.5% on 
average in the pressure cycle compared with the peristaltic pump harvest system. In 
addition, the duration time of the pressure cycle was decreased to 5 seconds from 8.7 
seconds in the peristaltic pump harvest system (Fig. 4.10). The duration time of exhaust 
cycle was 7 seconds in both harvest systems. This result means that it took less time to 
drive the water from the second chamber of a diaphragm pump to the bioreactor vessel.  
These results were probably due to the function of the check valve. When the 
check valve and the pinch valve were used instead of the peristaltic pump, there was no 
blockage of the harvest tube during the pressure cycle in the pinch valve off-time. In other 
words, there was little permeate back pressure due to the occlusion of harvest tube in the 
pressure time. This probably led to the reduction of permeate pressure and a resultant 
increase of permeate flux, which in turn resulted in decreased outlet flux. This caused a 
decrease of outlet pressure. Also, the decreases of both outlet and permeate pressure were 
accompanied by the decrease of inlet pressure. Since the flow-disturbing pressure, such as 
the outlet and permeate pressure, was decreased, the pressure cycle time was decreased 
under a constant driving force by a diaphragm pump in the ATF system. Consequently, it is 
obvious that the results as shown in Fig. 4.10 and Fig. 4.11 were due to this characteristic 






Fig. 4.8 Time profile of TMP during the pinch valve on-time in the modified harvest 
system. Transmembrane pressure (thick solid line), inlet pressure (solid line), outlet 
pressure (gray line) and permeate pressure (dashed line). Psig is the abbreviation of pounds 











Fig. 4.9 Time profile of TMP during the pinch valve off-time in the modified harvest 
system. Transmembrane pressure (thick solid line), inlet pressure (solid line), outlet 
pressure (gray line) and permeate pressure (dashed line). Psig is the abbreviation of pounds 
























Fig. 4.10 Results of TMP measurement during pinch valve off-time (thick solid line) 
and peristaltic pump on-time (thick dashed line). P: pressure cycle. E: exhaust cycle. 
Psig is the abbreviation of pounds per square inch gage. Error bars represent standard 
























Fig. 4.11 Comparison of peak pressures. P: pressure cycle. Inlet: inlet pressure. outlet: 
outlet pressure. permeate: permeate pressure. Psig is the abbreviation of pounds per square 
inch gage. E: exhaust cycle. Error bars represent standard deviations with n=3. *P < 0.001 









4.10 Conclusions  
In Chapter IV, it was described the development and experimental verification of 
a modified harvest system to enhance Factor VIII (FVIII) yield in an alternating tangential 
flow (ATF) perfusion culture. The modified harvest system was composed of a check 
valve, pinch valve and timer. The main innovation of the system is the use of check and 
pinch valves, eliminating the need of a peristaltic pump for harvest. The performance of the 
modified harvest system was compared with a peristaltic pump in terms of TMP across 
hollow fiber membrane. The system was successfully applied to ATF perfusion culture.  
As expected, the permeate pressure was decreased by the use of a check valve 
and a pinch valve. As a result of the decrease of permeate pressure, the modified harvest 
system achieved the higher TMP compared with a peristaltic pump harvest system. 
The increased TMP was due to the characteristic function of a check valve. 
When the check valve was used instead of the peristaltic pump, there was no blockage of 
the harvest tube during the pressure cycle in the pinch valve off-time. This resulted in the 
reduction of permeate pressure. The increase of TMP was due to the reduction of permeate 
pressure. 
In Chapter III, it was shown that TMP across a hollow fiber filter is as key factor 
in increasing the product yield of FVIII in an ATF perfusion culture. Thus, it was suggested 
that the modified harvest system developed in this study could be useful to enhance the 












Application of the modified harvest system 



















5.1 Cell growth and FVIII production 
In Chapter V, the performance of the modified harvest system was compared 
with that of the peristaltic pump harvest system. Fig. 5.1 shows the results of cell growth 
and FVIII production in ATF no. 1 and ATF no. 2 as described in Chapter II. Although 
there was an approximate 2-fold difference in seeding densities, the overall cell growth 
pattern was comparable in ATF no. 1 and ATF no. 2, except for the late stage of the runs. 
From cell growth results, the modified harvest system showed the possibility of its 
application to ATF perfusion culture. 
In addition to cell growth, the control of perfusion rate is especially important in 
perfusion culture. As shown in Fig. 5.1, the perfusion rate was successfully controlled 
using the modified harvest system composed of a check valve and a pinch valve without a 
conventional peristaltic pump.  
Unlike cell growth, ATF no. 1 and ATF no. 2 showed markedly different profiles 
of FVIII production. In ATF no. 1, The FVIII:C in bioreactor continuously increased over 
culture time. In Chapter III, it was demonstrated that the increase of FVIII:C in bioreactor 
was due to the increase of the retained FVIII:Ag. Contrary to ATF no. 1, there was only a 
marginal increase in FVIII:C in ATF no. 2 over time. The average FVIII:C in the ATF no. 2 
bioreactor was decreased to 67% compared with ATF no. 1. From this result, it is inferred 
that the retention of FVIII:Ag may be decreased in ATF no. 2 compared with ATF no. 1. 
This difference of FVIII:C in two harvest systems was further analyzed in the following 
section. 
Despite the low average FVIII:C in the bioreactor, these results indicate the 
potential of the modified harvest system as an alternating method to replace a peristaltic 







Fig. 5.1 Cell growth and FVIII production profile. Viable cell density of ATF no. 1 run 
(open square) and ATF no. 2 run (closed square). FVIII:C in bioreactor of ATF no. 1 run 
(open bar) and ATF no. 2 run (solid bar). Perfusion rate of ATF no. 1 run (dashed line) and 
ATF no. 2 run (solid line). AU indicates arbitrary unit. Error bars represent standard 










5.2 Analysis of recovery and product yield  
FVIII production profiles were examined in detail to evaluate the effect of the 
modified harvest system on FVIII:C recovery (Fig. 5.2 and Fig. 5.3). Both ATF no. 1 and 
ATF no. 2 showed the same decreasing pattern of recovery yield over the perfusion time. 
However, the final recovery yield was 3.5% in ATF no. 1 and 47.4% in ATF no. 2 (Fig. 
5.2). In comparison with ATF no. 1, ATF no. 2 achieved a 13.6-fold increase in the final 
recovery yield and a 4.3-fold increase in the average recovery yield.  
The product yield was also increased in ATF no. 2 compared with ATF no. 1 (Fig. 
5.3). In ATF no. 1, the product yield was decreased to 58.7%. In ATF no. 2, the product 
yield exceeded 85% after perfusion day 10. In comparison with ATF no. 1, ATF no. 2 
achieved a 1.47-fold increase in the product yield.  
These results indicate that the modified harvest system was more efficient in 
harvesting the produced FVIII than the peristaltic pump system. 
 
 
5.3 Analysis of the retention of proteins 
The retention of the produced proteins in ATF no. 1 and ATF no. 2 runs was 
examined (Fig. 5.4). A comparable pattern was observed in the recovery yields of three 
proteins in ATF no. 2. The recovery yields of FVIII:Ag and vWF:Ag were decreased over 
the perfusion time as the recovery yield of FVIII:C was decreased. This indicated the 
retention of FVIII and vWF molecules by the hollow fiber filter in the modified harvest 
system. 
 Compared with ATF no. 1 data, the recovery yield of FVIII:Ag of ATF no. 2 
was increased 2.4-fold at day 11, 4.5-fold at day 16 and 17.9-fold at day 35, respectively. 
Furthermore, the recovery yield of vWF:Ag of ATF no. 2 was also increased 2.6-fold at 
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day 11, 3.2-fold at day 16 and 16.4-fold at day 35, respectively.  
Taken together, these results indicate that the retention of proteins by the hollow 
fiber filter was significantly reduced by the modified harvest system (P < 0.05, two-tailed 
Student’s t-test), and that the enhancement of the recovery yield of FVIII:C was due to the 
reduction of retained FVIII:Ag by the hollow fiber filter. 
 
5.4 Conclusions  
In this study, the modified harvest system described in Chapter IV was applied in 
an ATF perfusion culture for FVIII production. The system achieved the comparable cell 
growth compared with a peristaltic pump harvest system. In addition, the perfusion rate 
was successfully controlled by combining a check valve and a pinch valve. These results 
imply that the modified harvest system can be an alternating method to replace a peristaltic 
pump harvest system in ATF perfusion culture. 
As a result of the increased TMP described in Chapter IV, the modified harvest 
system achieved the enhancement of the recovery and product yield of FVIII:C. This 
modified harvest system could be beneficial to the enhancement of the yield of other 
recombinant proteins using an ATF system.  
Taken together, the modified harvest system for ATF perfusion culture was 
successfully applied in a perfusion culture for FVIII production. Moreover, the modified 
harvest system offers an efficient alternating method for harvesting and provides a 
promising tool to solve the fouling problem in the filtration-based perfusion system, 









Fig. 5.2 FVIII:C recovery yield of ATF no. 1 run (open square) and ATF no. 2 run 
(closed square). Error bars represent standard deviations with n=2. The recovery yield was 












Fig. 5.3 FVIII:C product yield of ATF no. 1 run (open square) and ATF no. 2 run 
(closed square). Error bars represent standard deviations with n=2. The product yield was 
calculated by the ratio of the accumulated harvested FVIII:C and the total accumulated 
cellular production. The total accumulated cellular production = the accumulated harvested 











Fig. 5.4 Time profiles of FVIII:C recovery yield (circle), FVIII:Ag recovery yield 
(square) and vWF:Ag recovery yield (triangle). ATF no. 1 run: open symbol and right y-
axis. ATF no. 2 run: closed symbol and left y-axis. Error bars represent standard deviations 


































In this thesis, it was reported for the first time that the FVIII yield in ATF 
perfusion culture is significantly low compared to spin-filter and Centritech Lab III 
perfusion culture. Since the reduction of target protein yield by fouling of the hollow fiber 
filter is an inherent problem of filtration based perfusion culture, the possibility of yield 
reduction due to fouling obviously exists even in ATF perfusion culture. Even after 
considering the possibility of reduction in protein retention caused by filter fouling in the 
bioreactor, the FVIII:C recovery yield was unusually low in this thesis. 
The first study described in Chapter III aims to investigate the reasons for the 
unexpected low FVIII:C recovery yield in the ATF perfusion culture. It was assumed that 
three possible mechanisms could lead to a very low FVIII:C recovery yield in ATF 
perfusion culture. Firstly, the inactivation of secreted FVIII by temperature or various 
enzymes secreted by the CHO cells during storage of the harvest in the refrigerator until 
the replacement into a new harvest bag. Secondly, the reduction of the amount of FVIII:Ag 
itself by adsorption of FVIII molecule onto the harvest bag surface. Lastly, the reduction of 
the FVIII:Ag amount by molecular sieving through hollow fiber filter membrane. 
To verify these assumptions, it was firstly examined the inactivation and surface 
adsorption of FVIII molecule during storage at 4oC. The significance of TMP across the 
hollow fiber filter membrane was investigated. The results described in Chapter III 
successfully demonstrated that the low FVIII:C recovery yield in ATF perfusion culture 
was not due to the inactivation or surface adsorption of FVIII molecule, but due to the 
retention of the FVIII molecules by hollow fiber filtration. From the results of the 
controlled TMP experiments, the controlled TMP below 10psi resulted in remarkable 
enhancement of FVIII yield in hollow fiber filtration. From these observations, it was 
concluded that the TMP across hollow fiber filter is a key factor to increase the product 
yield of FVIII in ATF perfusion culture. 
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In Chapter IV, it was investigated how the TMP across hollow fiber filter can be 
increased. In a peristaltic pump harvest system, the increase of TMP was limited due to the 
continuous occlusion of harvest tube. Therefore, a modified harvest system was developed 
to overcome the limitation of a peristatic pump harvest system.  
To maximize the effect of transmembrane on the FVIII yield, the modified 
harvest system consisting of check valve, pinch valve and timer was developed. The 
performance of the modified harvest system was compared to a peristaltic pump. It was 
demonstrated that the modified harvest system achieved the enhancement of the recovery 
and product yield of FVIII compared to the peristaltic pump system. The final recovery 
yield of FVIII:C was increased an approximately 13.6-fold and the product yield of 
FVIII:C was increased a 1.47-fold compared with a peristaltic pump. The core technology 
of the modified harvest system is the use of a check valve. A check valve is a one-way 
valve which allows the flow of fluid in only one direction. The check valve enables the 
permeate pressure to be minimized during the pressure cycle in ATF perfusion. This 
characteristic function of the check valve enabled to achieve the increased TMP and the 
enhancement of FVIII yield.  
 However, it is not clearly elucidated in this thesis that why the FVIII yield is 
decreased with the increased TMP over 10psi. It was inferred that the co-expressed vWF is 
another factor affecting the retention of FVIII:Ag because of the molecular size of the 
FVIII/vWF complex. Thus, subsequent studies investigating the effect of the co-expressed 
vWF on the FVIII yield as well as the mechanism by which the FVIII yield is 
unexpectedly decreased under the increased TMP at more than 10psi should be performed.  
In addition, further studies are needed to develop a precise control method of 
TMP for the controlled TMP experiments. In this thesis, KrosFlo Research IIi system was 
used for the TMP control experiments. This system has a resolution problem of its 
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recording software used. The minimum data collection period of the recording software is 
1 second. ‘1 second’ does not seem to be enough to collect the data to show a precise TMP 
profile. Therefore, it was thought that if a higher-resolution recording software is used to 
collect data, a more precise TMP control can be obtained. Through the precise TMP control, 
it is possible to determine an optimal TMP for the maximum FVIII yield. 
 This thesis clearly showed that the modified harvest system developed in this 
thesis achieved the enhancement of FVIIII yield compared to the peristaltic pump harvest 
system. However, although the FVIII:C recovery yield was enhanced by using the 
modified harvest system as described in Chapter IV, the FVIII:C recovery yield was still 
lower than that of spin-filter and Centritech Lab III perfusion. The average recovery yield 
of FVIII:C in ATF perfusion with the modified harvest system was 64.6%. Whereas, the 
average recovery yield of FVIII:C was 92.8% in spin-filter perfusion and 81.7% in 
Centritech Lab III perfusion, respectively. These results indicate that ATF system has a 
limitation due to the molecular sieving of FVIII/vWF complex by hollow fiber filter. Thus, 
spin-filter or Centritech Lab III centrifuge system might be more efficient and suitable than 
ATF system in the production of FVIII co-expressed with vWF. 
In conclusion, the modified harvest system of this thesis offers an efficient 
alternating method for harvesting in ATF perfusion culture. The system can be beneficial to 
other recombinant proteins production using ATF system as well. Another important point 
is that the system provides a promising tool to solve the fouling problem in the filtration-
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본 학 논  목  ATF 류식 배양에  액 고 8 인자 (Factor 
VIII)  생산  향상시키  한 개  회 장치를 공하는 것이다. 
이를 하여 체크밸 , 핀치밸  타이  구  개  회 장치를 개발
함 써 본 학 논  목  달 하 다. 
 
 본 학 논   개  연구  구 었다. 첫 번째 연구에 는 ATF 
류식 배양에  액 고 8 인자  회  이 낮  이 에 하여 고
찰하 다. 폰 리 란트 인자(vWF)  동시에 발 는 재조합 인간 액
고 8 인자  생산  하여 류식 배양에 리 사용 는 ATF 시스 , 
spin-filter, Centritech Lab III centrifuge 등과 같   가지  포체류장
치(cell retention device)를 평가하 다. 그 결과, ATF 류식 배양에  다
른  개  포체류장치에 해 바이 리액  안  액 고 8 인자  
이 매우 높  발견하 다. 욱이, 액 고 8 인자  회  이 
ATF 류식 배양에  다른  개  포체류장치에 해 상외  매우 낮
 발견하 다. 
 
첫 번째 연구결과를 통해 재조합 액 고 8 인자 분자  회 용 면
 착(surface adsorption)과 불 (inactivation)는 ATF 류식 배
양에  낮  에 한 주요 원인이 아님  인하 다. 재조합 액 고 
8 인자   류식 배양에 사용 는 공사막(hollow fiber filter 
membrane)  공극 크 (pore size)를 0.2mm 에  0.5mm  증가시켰  경
우에도 향상 지 않았다. 또한, 공사막에 한 재조합 액 고 8 인자 
분자  잔류가 ATF 류식 배양에  낮  액 고 8 인자   
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주요 원인이었  알아내었다. 우리는 공사막에 가해지는 막간압
(transmembrane pressure)를 조 함 써 액 고 8 인자 이 크게 
향상  보여주었다. 이러한 연구결과를 종합하여보면 막간압  조 이 
ATF 류식 배양에  액 고 8 인자   향상  한 효 인 방법
이   있  시사하고 있다. 
 
 번째 연구에 는 ATF 류식 배양에  액 고 8 인자  향
상시키  한 개  회 장치  개발에 하여 하 다. 본 연구에 는 
막간압  향상시킬  있는 개  회 장치를 개발함 써 ATF 류식 
배양에  낮  액 고 8 인자 회   향상시킬  있는 가능  
시하 다. 개  회 장치에  주요한 신 인 개  회 를 한 연
동펌프(peristaltic pump)  사용  배 할  있는 체크밸  핀치밸  
사용이다. 액 고 8 인자가 포함 어있는 배양상등액 회 를 한 이 
항상 막 있는 연동펌프 회 장치에 는 ATF 류식 배양에  액 고 
8 인자  향상  요한 요인인 막간압  증가시키는 데 한계가 있다. 
그러나, 개  회 장치에 는 연동펌프 신 체크밸 를 사용함 써 과
압  (permeate pressure)  44.8% 감소시킬  있었 며, 이  인해 막간
압  96%이상 향상시킬  있었다.  
 
 번째 연구에 는 개  회 장치  액 고 8 인자  폰 리 란
트 인자를 동시에 발 하는 국 햄스  난소 포(Chinese hamster 
ovary(CHO) cell)  류식 배양에  용에 하여 하 다. 개  회
장치는 연동펌프를 사용한 종래  회 장치  동등한 포 장  보여주었
다. 류속도(perfusion rate)도 개  회 장치를 이용하여 공  조
었다. 또한, 개  회 장치는 연동펌프  하   액 고 8
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인자  종 회   약 13.6 배, 액 고 8 인자  생산 
 약 1.47 배 증가시켰다. 개  회 장치에 한 액 고 8 인자 
  향상  액 고 8 인자 분자  잔류량 (the retention of 
FVIII:Ag)  감소에 인하 다.  
 
막간압  측  결과 부 , 연동펌프 회 장치   시 잔류  액
고 8 인자 분자  감소는 증가  막간압 에 인하며, 이러한 막간압  
증가는 체크밸  특징 인 능에 한 것임  알게 었다.  
 
결  본 연구를 통해 개발  개  회 장치를 이용하여 ATF 류
식 배양에  재조합 액 고 8 인자 생산  향상시킬  있었다. 또
한, 개  회 장치는 재조합 액 고 8 인자 뿐만 아니라 다른 재조합 
단백질  생산  향상시키는데 용할 것  다.  
 
본 학 논 에  얻  또 다른 요한 과는 개  회 장치가 ATF 
류식 배양과 같  여과 반 류식 배양 (filtration-based perfusion) 시스
 내재 인 인 분리막 손 (membrane fouling) 를 근본  
해결할  있는 망한 방법  시하 다는 데 있다. 
 
주 어: 혈액응고 제8인자, ATF perfusion, 개선된 회수장치, 막간압력, 
핀치밸브, 체크밸브 
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